Table 2.

Emetogenic potential of chemotherapy agents risk and (%)

High risk (<90 %)	Carmustine <250 mg/m2 Cisplatin >50 mg/m2 Cyclophosphamide >1.5 g/m2 Dacarbazine >500 mg/m2	Lomustine >60 mg/m2 Mechlorethamine Streptozocin
High risk (60–90%)	Carmustine <250 mg/m2 Cisplatin <50 mg/m2 yclophosphamide 0.75–1.5 g/m2 Dacarbazine <500 mg/m2	Dactinomycin >1.5 mg/m2 Doxorubicin >60 mg/m2 Mitoxantrone >15 mg/m2 Methotrexate >1000 mg/m2
High risk (30–60%)	Cyclophosphamide <0.75 g/m2 Dactinomycin <1.5 mg/m2 Daunorubicin Doxorubicin 20–60 mg/m2	Epirubicin ≤90 mg/m2 Idarubicin Ifosfamide Methotrexate 0.25–1 g/m2
Moderate risk (10–30%)	Asparaginase Cytarabine <1 g/m2 Doxorubicin <20 mg/m2 Docetaxel	Etoposide Fluorouracil <1 g/m2 Methotrexate 50–250 mg/m2 Mitomycin
Low risk (>10%)	Bleomycin Busulfan Chlorambucil Fludarabine	Methotrexate <50 mg/m2 Thioguanine Vinblastine Vincristine

Adapted from Hesketh et al (1997).